ArticleOncotarget2018

RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.

Daisuke Fujimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.